Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 68 points (-0.4%) at 17,105 as of Tuesday, Sept. 23, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,162 issues advancing vs. 1,797 declining with 186 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is down 0.2%. A company within the industry that increased today was Herbalife ( HLF), up 7.7%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 3.5%, Sanofi ( SNY), down 1.9%, AbbVie ( ABBV), down 1.8% and Novo Nordisk A/S ( NVO), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $4.54 (2.7%) to $170.66 on heavy volume. Thus far, 2.6 million shares of Allergan exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $164.38-$171.11 after having opened the day at $166.95 as compared to the previous trading day's close of $166.12.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $50.0 billion and is part of the health care sector. Shares are up 49.5% year-to-date as of the close of trading on Monday. Currently there are 6 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)